Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2021

View Archived Issues

Osmol initiates IND-enabling studies of OSM-0205 for prevention of CIPN

Regeneron's REGN-7483F Mini-VEGF-Trap could be a next-generation VEGF inhibitor

Phase II/III XIRIUS study of cotoretigene toliparvovec in XLPR does not meet primary endpoint

SK Biopharmaceuticals divulges PRMT5 inhibitors

Gilead Sciences patents GLP-1R agonists

Kinnate Biopharma synthesizes new Raf kinase C inhibitors

ARKUDA Therapeutics identifies PGRN modulators

Shire Human Genetic Therapies describes new AAV-based gene therapy for HAE

CureVac reports promising preclinical data for its second-generation COVID-19 vaccine candidate

Combined administration of BNT-152 and BNT-153 results in synergistic antitumor effects

FDA approves Empaveli for PNH

Clinical results of an individualized multimodal immunotherapy

Phase II data on Sanofi and GSK COVID-19 vaccine candidate show favorable immune responses

Memo's MTX-COVAB shows efficacy against original SARS-CoV-2 and U.K. variant

Phase I results presented for rAAV9.U7snRNA.ACCA in DMD

Seelos reports open-label data on SLS-002 for acute suicidal ideation and behavior in MDD

New murine model of myotonic dystrophy 1 developed

Rise Biopharmaceuticals initiates phase I study of RP-72 in pancreatic cancer

Australian researchers map out first genetic profile of skeletal master regulator cells

Galera begins dosing in phase IIb study of GC-4711 in pancreatic cancer

Phase III trials of ruxolitinib in vitiligo meet endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...